歌禮製藥-B(01672.HK)今年以來利托那韋片預收款累達5,500萬人幣
歌禮製藥-B(01672.HK)公布,截至目前,今年基於不可撤銷訂單的利托那韋片的預收款(含稅,未經審計)已達約5,500萬元人民幣。鑑於2023年新冠疫情仍存在不確定性,公司對2023年全年的利托那韋片銷售收入保持謹慎。
此外,截至目前,在計劃的50名患者中,皮下注射PD-L1抗體ASC22(恩沃利單抗)用於乙肝功能性治癒的IIb期擴展隊列已完成29例慢性乙型肝炎患者入組。該IIb期擴展隊列期中數據預計於今年第三季公布。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.